Evidence map›Paper›PMID 36969187›Full record

ArticleFrontiers in immunology2023

Fatty acid transport protein inhibition sensitizes breast and ovarian cancers to oncolytic virus therapy

Abera Surendran, Monire Jamalkhah, Joanna Poutou, Rayanna Birtch, Christine Lawson, Jaahnavi Dave, Mathieu J F Crupi, Justin Mayer, Victoria Taylor, Julia Petryk and 19 more

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 4 institutions in 1 country.

Abera SurendranOttawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON, Canada.
Monire JamalkhahOttawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON, Canada.
Joanna PoutouOttawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON, Canada.
Rayanna BirtchOttawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON, Canada.
Christine LawsonDepartment of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada.
Jaahnavi DaveOttawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON, Canada.
Mathieu J F CrupiOttawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON, Canada.
Justin MayerOttawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON, Canada.
Victoria TaylorOttawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON, Canada.
Julia PetrykOttawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON, Canada.
Christiano Tanese de SouzaOttawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON, Canada.
Neil MoodieOttawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON, Canada.
Jacob Lecompte BillingsleyOttawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON, Canada.
Bradley AustinOttawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON, Canada.
Nicole CormackOttawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON, Canada.
Natalie BlameyOttawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON, Canada.
Reza RezaeiOttawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON, Canada.
Curtis W McCloskeyOttawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON, Canada.
Emily E F FeketeOttawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON, Canada.
Harsimrat K BirdiOttawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON, Canada.
Serge NeaultOttawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON, Canada.
Taylor R JamiesonOttawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON, Canada.
Brenna WylieOttawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON, Canada.
Sarah TuckerOttawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON, Canada.
Taha AzadOttawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON, Canada.
Barbara VanderhydenOttawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON, Canada.
Lee-Hwa TaiDepartment of Immunology and Cell Biology, Université de Sherbrooke, Sherbrooke, QC, Canada.
John C BellOttawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON, Canada.
Carolina S IlkowOttawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON, Canada.
Ottawa Hospital Research InstituteUniversity of Ottawa · CAOttawa Hospital · CAUniversité de Sherbrooke · CA

Funding

CIHR 377104
6 · The paper itself

Abstract

Introduction: Adipocytes in the tumour microenvironment are highly dynamic cells that have an established role in tumour progression, but their impact on anti-cancer therapy resistance is becoming increasingly difficult to overlook. Methods: We investigated the role of adipose tissue and adipocytes in response to oncolytic virus (OV) therapy in adipose-rich tumours such as breast and ovarian neoplasms. Results: We show that secreted products in adipocyte-conditioned medium significantly impairs productive virus infection and OV-driven cell death. This effect was not due to the direct neutralization of virions or inhibition of OV entry into host cells. Instead, further investigation of adipocyte secreted factors demonstrated that adipocyte-mediated OV resistance is primarily a lipid-driven phenomenon. When lipid moieties are depleted from the adipocyte-conditioned medium, cancer cells are re-sensitized to OV-mediated destruction. We further demonstrated that blocking fatty acid uptake by cancer cells, in a combinatorial strategy with virotherapy, has clinical translational potential to overcome adipocyte-mediated OV resistance. Discussion: Our findings indicate that while adipocyte secreted factors can impede OV infection, the impairment of OV treatment efficacy can be overcome by modulating lipid flux in the tumour milieu.

Indexed as

Oncolytic VirotherapyOncolytic VirusesOvarian NeoplasmsCulture Media, ConditionedFemaleHumansLipidsTumor MicroenvironmentCulture Media, ConditionedLipidsadipocytesbreast cancerfatty acidsoncolytic virusesovarian cancertumor microenvironmentviral-based therapeutics

Identifiers

PMID36969187
PMCPMC10036842
OpenAlexW4323856878

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read104
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.